**Supernus Pharmaceuticals Reports 2025 Financial Results, Highlights Strategic Acquisition**
Supernus Pharmaceuticals, Inc. (SUPN) reported total revenues of $719.0 million for the year ended December 31, 2025, an increase of 9% compared to $661.8 million in 2024. The company experienced a net loss of $38.6 million, compared to net earnings of $73.9 million in the previous year. This decline in profitability was primarily attributed to higher amortization of intangible assets, increased selling, general, and administrative expenses, and a contingent consideration loss, largely stemming from the acquisition of Sage Therapeutics.
A significant strategic development for Supernus in 2025 was the acquisition of Sage Therapeutics, Inc., completed on July 31, 2025, for approximately $561 million in cash plus contingent value rights. This acquisition brought ZURZUVAE® into Supernus's portfolio, contributing $53.0 million in collaboration revenue for the year. The company also launched ONAPGO™ in April 2025, a novel treatment for motor fluctuations in Parkinson's Disease, which generated $17.3 million in net product sales.
Key operational developments included the continued growth of Qelbree®, with net product sales increasing by 26% to $304.7 million, and GOCOVRI®, with a 12% increase to $146.8 million. However, Oxtellar XR® and Trokendi XR® experienced declines in net product sales due to generic erosion, decreasing by 59% and 33%, respectively. APOKYN® sales also decreased by 35% due to lower volume. The company employed 778 full-time employees as of December 31, 2025, and maintained key customer relationships with Cencora, Cardinal Health, and McKesson Corporation, which collectively accounted for over 76% of total product revenue.
Looking ahead, Supernus faces challenges including supplier constraints impacting ONAPGO demand, generic competition for existing products, and the successful integration of Sage Therapeutics. The company's strategy includes driving growth and profitability of key marketed products, advancing product candidates toward commercialization, and targeting strategic business development opportunities. The company's cash, cash equivalents, and marketable securities totaled $310.1 million as of December 31, 2025, which management believes will be sufficient to satisfy its cash requirements over the next twelve months and beyond.
About SUPERNUS PHARMACEUTICALS, INC.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company specializing in developing and commercializing treatments for central nervous system (CNS) disorders. Its portfolio includes products for ADHD, Parkinson's disease, epilepsy, migraine, and dystonia. The company leverages proprietary technologies and strategic licensing to create innovative, patient-friendly medications, focusing on improving efficacy, safety, and adherence. It markets primarily in the U.S. through direct sales and partnerships.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.